---
title: "ZYPEEK: Net profit of 7.0269 million yuan in the first half of 2025, a year-on-year decrease of 59.89%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254772682.md"
description: "ZYPEEK announced that its operating revenue in the first half of 2025 was 131 million yuan, a year-on-year decrease of 2.10%. The net profit was 7.0269 million yuan, a year-on-year decrease of 59.89%"
datetime: "2025-08-27T09:26:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254772682.md)
  - [en](https://longbridge.com/en/news/254772682.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254772682.md)
---

# ZYPEEK: Net profit of 7.0269 million yuan in the first half of 2025, a year-on-year decrease of 59.89%

ZYPEEK announced that its operating revenue in the first half of 2025 was 131 million yuan, a year-on-year decrease of 2.10%. Net profit was 7.0269 million yuan, a year-on-year decrease of 59.89%

### Related Stocks

- [688716.CN](https://longbridge.com/en/quote/688716.CN.md)

## Related News & Research

- [Best of BS Opinion: FTA strains, virus alerts, and market reform debate](https://longbridge.com/en/news/286835751.md)
- [Europe-China spacecraft launches to study Earth's 'invisible armour'](https://longbridge.com/en/news/286881963.md)
- [Marvel Biosciences Announces Grant of Deferred Share Units | MBCOF Stock News](https://longbridge.com/en/news/287056256.md)
- [Apple Flavor to Buy NovoSana’s China Assets for Up to USD66 Million in Health Supplements Push](https://longbridge.com/en/news/287039106.md)
- [20:00 ETAccro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases](https://longbridge.com/en/news/286830151.md)